[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Julka PK, Puri T, Rath GK: A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2006 Feb;5(1):110-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
  • BACKGROUND: Patients with carcinoma of the gallbladder have advanced, unresectable tumor at the time of presentation and face a dismal prognosis in the absence of a standard palliative chemotherapy regimen.
  • This study was undertaken to evaluate the efficacy and safety of combined chemotherapy of gemcitabine and carboplatin in 20 patients with advanced gallbladder carcinoma.
  • METHODS: The criteria of eligibility included chemonaive patients with unresectable gallbladder cancer, bidimensionally measurable disease, Zubrod's performance status < or = 2, and adequate major organ function.
  • RESULTS: In this group of 20 patients with advanced gallbladder carcinoma 6 were men and 14 women, with a median age of 55 years.
  • The stage of the tumor at presentation was IVB in 14 patients (70%), IVA in 3 (15%) and III in 3 (15%).
  • The median time to progression of the tumor was 33.8 weeks, and 1-year survival rate of the patients was 43.3%.
  • CONCLUSION: With mild toxicity, combined chemotherapy of gemcitabine and carboplatin is effective in the treatment of advanced gallbladder carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481295.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


2. Azria D, Seblain-El-Guerche C, Girard N, Hennequin C, Huguet F: [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review]. Bull Cancer; 2008 Nov;95(11):1116-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].
  • [Transliterated title] Intérêt de la chimioradiothérapie dans la prise en charge des adénocarcinomes du pancréas localement avancés : revue systématique.
  • INTRODUCTION: At the request of the National Thesaurus of Gastrointestinal Cancer (TNCD), the SOR program undertaken by the French Federation of Cancer Centers (FNCLCC) and now led by the French National Cancer Institute (INCa), completed a systematic review to evaluate the value of chemoradiotherapy (CRT) in the management of locally advanced pancreatic adenocarcinoma in collaboration with clinician experts.
  • All phase III randomized trials and systematic reviews concerning non resectable locally advanced pancreatic adenocarcinoma and non metastatic (stage III) were included in the study.
  • Some phase II trials were also included if no phase III trials were retrieved.
  • The following interventions were compared: CRT versus best supportive care (BSC), CRT versus radiotherapy, and CRT versus chemotherapy.
  • The modalities of CRT regimens and the sequences of chemotherapy-CRT versus CRT were also studied.
  • Concomitant CRT compared to chemotherapy alone is not superior in terms of survival (B1) and increases toxicity (A).
  • Concerning administration modalities of radiotherapy, recent data are in favour to a limited irradiation to the tumoral volume (C) and to a total dose of 50-60 Gy in association with 5-FU.
  • The study of radiotherapy associated drugs shows that 5-FU is the reference (B1) and the value of gemcitabine must be proved in randomized trials.
  • Finally, the study of sequences chemotherapy-CRT has recently showed that induction chemotherapy before CRT improves survival (C).
  • CONCLUSION: The use of CRT for locally advanced pancreatic adenocarcinoma is based on a few randomized trials even if this treatment appears superior in terms of survival compared to BSC and radiotherapy alone.
  • This review shows the need to conduct other specific randomized trials in order to validate the value of CRT, especially compared to chemotherapy alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Pancreatic Ductal / drug therapy. Carcinoma, Pancreatic Ductal / pathology. Clinical Trials, Phase III as Topic. Combined Modality Therapy / methods. Humans. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036684.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


3. Ozkok S, Demirci S, Yalman D, Zeytunlu M, Nart D, Yuzer Y, Coker A, Goker E: Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma. Tumori; 2010 Jul-Aug;96(4):560-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
  • AIMS AND BACKGROUND: To evaluate the treatment results of gemcitabine alone and concurrent with radiotherapy after R0/R1 resection of locally advanced pancreatic cancer.
  • METHODS AND STUDY DESIGN: From 1999 to 2005, 55 patients with stage II resected pancreatic cancer treated with gemcitabine-based radiochemotherapy were retrospectively evaluated.
  • RESULTS: Thirteen patients were stage IIA and 42 were stage IIB.
  • All of the patients received induction chemotherapy and radiotherapy, all but 3 received concurrent radiochemotherapy, and 46 (84%) patients received maintenance chemotherapy.
  • In multivariate analysis, nodal stage, AJCC stage and number of lymph nodes dissected were the significant factors affecting disease-free survival whereas Karnofsky performance status was the only significant factor for overall survival.
  • CONCLUSIONS: The prognosis for pancreatic cancer remains poor despite adjuvant radiochemotherapy.
  • More aggressive treatments should be considered in patients with unfavorable prognostic factors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Deoxycytidine / analogs & derivatives. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20968135.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


Advertisement
4. Saif MW, Sviglin H, Carpenter M: Impact of ethnicity on outcome in pancreatic carcinoma. JOP; 2005 May;6(3):246-54
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of ethnicity on outcome in pancreatic carcinoma.
  • In pancreatic cancer, African Americans are thought to have a higher incidence and poorer prognosis than Whites.
  • PATIENTS: A total 645 pancreatic cancer patients were identified in the database, of which, 530 patients were eligible for this study and retained for the statistical analysis.
  • Overall, 132 patients out of 415 (31.8%) were seen in stage I, 61 (14.7%) in stage II, 105 (25.3%) in stage III, 117 (28.2%) in stage IV, while 115 patients (21.7%) had missing stage.
  • Overall, 125 (23.6%) received surgery alone, 54 (10.2%) surgery with chemotherapy, 5 (0.9%) surgery with external radiation therapy, 10 (1.9%) external radiation therapy alone, 68 (12.8%) chemotherapy alone, 58 (10.9%) chemo-external radiation therapy, and 210 (39.6%) no therapy.
  • There were more survivors in females (43/255, 16.9%) than in males (25/275, 9.1%; P=0.009), and females had significantly greater survival times as compared to males (P=0.022).
  • CONCLUSIONS: Pancreatic cancer is a disease of both ethnicities with a slight male predominance among Whites and female predominance among Blacks.
  • We did not find any significant difference in the treatment specific outcome and survival between Blacks and Whites.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / therapy. African Americans. European Continental Ancestry Group. Pancreatic Neoplasms / ethnology. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Characteristics. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15883475.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Zalatnai A: Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. Cancer Treat Rev; 2007 May;33(3):289-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
  • Pancreatic cancer is still a malignant disease of grim prognosis despite all therapeutic efforts.
  • Because clinical symptoms in the early stage are usually absent or aspecific, it is frequently discovered at advanced or metastatic stage, only around 15-20% of tumors are resectable.
  • In the majority of patients only the chemotherapy offers a prolongation of life, but even the first-line chemotherapeutic agent, the gemcitabine has a modest survival benefit, and objective tumor response is rarely achieved.
  • Nowadays, in the era of molecular-targeted oncotherapeutic approaches, pancreatic cancer is also a subject such trials: epidermal growth factor receptor blockade, inhibition of angiogenesis, modulation of tumor response through the extracellular matrix, inhibition of cyclooxygenase-2, farnesyl transferase inhibitors, signal transduction inhibitors, ablation of the hormonal influence and some other aspects have all been studies, but to date, no breakthrough in the treatment of pancreatic carcinoma is proven.
  • In several Phase II-III studies these compounds given alone displayed marginal effects, but when combined with the standard cytostatics, some beneficial effects were observed, however, some of them displayed a severe (sometimes fatal) toxicity.
  • To date, the role of the molecular targeted therapy in pancreatic carcinoma is promising, but the results are not convincingly superior to the standard chemotherapeutic treatments.
  • Pancreatic adenocarcinoma remains a great challenge for the oncologists, and continuous search for better molecules and/or combinations is inevitable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Cyclooxygenase 2 Inhibitors / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Drug Delivery Systems. Farnesyltranstransferase / antagonists & inhibitors. Hormone Antagonists / therapeutic use. Hormones. Humans. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343986.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Hormone Antagonists; 0 / Hormones; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 118
  •  go-up   go-down


6. Wang XY, Li HJ, Wen H, Yan D, Peng SY: Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma. Front Med China; 2010 Dec;4(4):430-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the adjuvant therapy on the survival of patients with stage II pancreatic carcinoma.
  • This study aimed to investigate the effect of adjuvant therapy on the treatment of stage II pancreatic carcinomas.
  • The clinical data of 139 cases of stage II pancreatic carcinoma were analyzed retrospectively.
  • The overall 1-, 3-, and 5-year cumulative survival rates of 139 patients were 40%, 6%, and 3%, respectively, and the median survival time (MST) was 279 days.
  • The MST was 399 days for those with adjuvant therapy, 210 days for those without adjuvant therapy, 390 days for the radical resection group, 270 days for the bypass operation and laparotomy group, and 132 days for the nonsurgical group.
  • The adjuvant therapy could not prolong the survival time and decrease the liver metastasis rate of the patients with stage II carcinoma significantly in radical resection group (P>0.05).
  • In the bypass operation and laparotomy group and nonsurgical group, the adjuvant therapy could improve the survival of the patients significantly (P<0.05); however, the survival rate was not significantly different among systemic venous chemotherapy, radiation therapy, interventional therapy, and combination therapy (P>0.05); or between gemcitabine (GEM) regimen and 5-fluorouracil regimen (P>0.05); or between GEM monotherapy and GEM combined with platinum/capecitabine (P>0.05).
  • The proper adjuvant therapy can be suggested according to the general condition of the patients after radical resection for stage II pancreatic carcinoma.
  • Chemotherapy combined with radiation should be applied actively for the patients whose cancerous tissues were not radically resected.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / therapy. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Pancreas. 1997 Aug;15(2):154-9 [9260200.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1626-41 [15887155.001]
  • [Cites] JOP. 2006 Jul 10;7(4):337-48 [16832131.001]
  • [Cites] Chin Med J (Engl). 2009 Feb 5;122(3):284-90 [19236805.001]
  • [Cites] JOP. 2008 Mar 08;9(2):91-8 [18326919.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Pancreas. 2009 Jan;38(1):30-5 [19117085.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:469-73 [10895197.001]
  • [Cites] Cancer Causes Control. 2006 May;17(4):403-9 [16596292.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4923-32 [11406572.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):300-9 [18216537.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2008 Mar 1;46(5):366-9 [18785534.001]
  • (PMID = 21191747.001).
  • [ISSN] 1673-7458
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L, Stillhart P, Pestalozzi B, Herrmann R: Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol; 2010 Dec;21(12):2390-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
  • BACKGROUND: Gemcitabine remains the mainstay of palliative treatment of advanced pancreatic carcinoma (APC).
  • The purpose of this study was to determine dose, safety and preliminary efficacy of a first-line regimen combining all three classes of active cytotoxic drugs in APC.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with locally advanced or metastatic, histologically proven adenocarcinoma of the pancreas were treated with a 21-day regimen of gemcitabine [1000 mg/m² day (d) 1, d8], escalating doses of oxaliplatin (80-130 mg/m² d1) and capecitabine (650-800 mg/m² b.i.d. d1-d14).
  • The recommended dose (RD), determined in the phase I part of the study by interpatient dose escalation in cohorts of three to six patients, was further studied in a two-stage phase II part with the primary end point of response rate by RECIST criteria.
  • RESULTS: Forty-five patients were treated with a total of 203 treatment cycles.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2011 Apr;22(4):987 [21289365.001]
  • (PMID = 20444846.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Malayeri R, Ghassemboland M, Ranjpoor F, Maadi A: Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. Hematol Oncol Stem Cell Ther; 2008 Oct-Dec;1(4):221-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma.
  • BACKGROUND AND OBJECTIVE: The response rate and median survival with gemcitabine monotherapy, although considered the standard treatment for inoperable and metastatic pancreatic cancer, is relatively poor.
  • We tested the efficacy and toxicity of a chemotherapy protocol consisting of gemcitabine, 5-fluorouracil (5-FU) and leucovorin in patients with inoperable or metastatic pancreatic cancer, which was shown to improve median survival in a small phase II trial.
  • PATIENTS AND METHODS: Patients older than 18 years of age with histologically or cytologically confirmed adenocarcinoma of the pancreas and bidimensionally measurable disease, and who were chemotherapy- and radiotherapy-naïve, were treated with a chemotherapy protocol consisting of gemcitabine 1250 mg/m2 on day 1, 5-FU 450 mg/m2 and leucovorin 100 mg/m2 on days 1-3.
  • The treatment was repeated every 2 weeks.
  • RESULTS: In an-intention-to-treat analysis, of 37 patients with pancreatic cancer (27 males, 10 females) (67.6% stage IVb) there were 7 (18.9%) objective partial responses (95% confidence interval, 8.33% to 29), 14 (37.8%) patients had stable disease and 16 (43.2%) had progressive disease.
  • The median response time was 3 months (range, 1.5 to 7.0 months).
  • Median overall survival time was 6.5 months (range, 1.0 to 15.5 months).
  • The response to chemotherapy was not different between males and females (P = .971).
  • CONCLUSION: Despite our poor survival data, the combination of gemcitabine with 5-/FU and leucovorin is an active and well-tolerated regimen in patients with pancreatic cancer that merits further evaluation in prospective randomized studies.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058477.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Liang QL, Pan DC, Yin ZM, Liu GX, Yang Q, Xie JR, Fu YW, Cai LZ: [Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Mar;28(3):214-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
  • OBJECTIVE: To detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy.
  • METHODS: The serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared.
  • RESULTS: Compared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer.
  • It was elevated gradually from stage II to IV (P < 0.01).
  • However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01).
  • CONCLUSION: The serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.
  • [MeSH-major] Antigens, CD95 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / drug therapy. Adult. Carcinoma, Pancreatic Ductal / blood. Carcinoma, Pancreatic Ductal / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875609.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA: Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J; 2009 Jul-Aug;15(4):339-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.
  • BACKGROUND: LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in pancreatic cancer xenograft models.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas were randomly assigned to gemcitabine 1000 mg/m on days 1, 8, and 15 of a 28-day cycle and continuously administered LY 600 mg twice daily or gemcitabine 1000 mg/m on days 1, 8, and 15 of a 28-day cycle and daily oral placebo.
  • Arms were balanced for Eastern Cooperative Oncology Group performance status and disease stage.
  • CONCLUSIONS: These results do not demonstrate any benefit to adding LY to gemcitabine in unpretreated patients with advanced pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Benzoates / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Double-Blind Method. Female. Humans. Male. Middle Aged. Receptors, Leukotriene B4 / antagonists & inhibitors. Treatment Outcome. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672152.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Benzoates; 0 / LY 293111; 0 / Receptors, Leukotriene B4; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Oettle H, Hilbig A, Seufferlein T, Schmid RM, Luger T, von Wichert G, Schmaus S, Heinrichs H, Schlingensiepen K: Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma.
  • Trabedersen, a TGF-beta 2-specific inhibitor has already shown a clear survival benefit in a randomized active-controlled phase II study in high-grade glioma patients, compared to standard chemotherapy.
  • METHODS: 33 patients with advanced pancreatic carcinoma (stage IVA/IVB) (N=23), malignant melanoma (stage III/IV) (N=5) or colorectal carcinoma (stage III/IV) (N=5) were treated with trabedersen as 2nd-4th-line treatment.
  • Two treatment schedules (1st schedule:7d on, 7d off; 2nd schedule: 4d on, 10d off; up to 10 cycles) were evaluated in a cohort dose-escalation design.
  • Median overall survival (mOS) for pancreatic carcinoma patients in the 1st schedule was 6.8 months.
  • One pancreatic carcinoma patient showed a complete response and is alive 38 months after trabedersen therapy.
  • Current mOS for pancreatic carcinoma patients in cohort 1 (N=5) of the 2nd schedule is 13.2 months; 2 of these patients are alive, one with stable disease 14.8 months after begin of trabedersen treatment.
  • A randomized, active-controlled phase II study compared to standard therapy in patients with pancreatic carcinoma is in preparation; another one in malignant melanoma is being planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol; 2009 May 20;27(15_suppl):e15578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.
  • : e15578 Background: Fluorouracil (5-FU) chemoradiotherapy has been accepted as standard care for locally advanced pancreatic cancer (LAPC); however, it has not been shown to be superior to chemotherapy alone in gemcitabine (Gem) era.
  • The present multicenter phase II study was conducted to evaluate the efficacy and the safety for the screening of Gem monotherapy against LAPC.
  • METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.
  • Patient characteristics were: median age; 67.5 (45-80), male/female; 35/15, PS 0/1/2; 30/20/0, pancreatic head/body-tail; 26/24.
  • There were no treatment-related deaths during the study.
  • In future randomized trial, we will select Gem chemotherapy as a referential arm to compare with the chemoradiotherapy regimen which is under phase II evaluation for LAPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Shi YX, Xu RH, Jiang WQ, Zhang L, Lin TY, Li YH, Xia ZJ, Luo HY, Han B, Wang F, He YJ, Guan ZZ: [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer]. Ai Zheng; 2007 Dec;26(12):1381-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
  • BACKGROUND & OBJECTIVE: Gemcitabine (GEM) is efficient in treating advanced pancreatic cancer.
  • But in China, the use of GEMOX regimen for advance pancreatic cancer has seldom been reported.
  • This study was to analyze the efficacy of GEMOX regimen on advanced pancreatic cancer, and observe the adverse events.
  • METHODS: Clinical data of 32 chemonaive patients with stage III-IV pancreatic cancer, treated with GEMOX regimen [intravenous injection of gemcitabine (1 000 mg/m(2)) at Day 1 and Day 8, and intravenous injection of oxaliplatin (85-130 mg/m(2)) at Day 1; repeated every 21 days] at Cancer Center of Sun Yat-sen University from Feb.
  • Liver function damage (grade I-II) occurred in 8 (25.0%) patients; peripheral neurotoxicity (grade I) occurred in 14 (43.8%) patients.
  • No chemotherapy-related death occurred.
  • CONCLUSIONS: GEMOX is an effective regimen for pancreatic carcinoma with good clinical tolerance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neutropenia / chemically induced. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Thrombocytopenia / chemically induced. Vomiting / chemically induced


14. Ychou M, Senesse P, Quénet F: [Update on gastroenterology]. Bull Cancer; 2000 Jun;87(6):455-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the field of mass detection of colorectal cancer by Hemoccul test, the results of the Burgundy study confirm the two european studies previously published and encourage to extend this training to the whole country.
  • When genetic markers are performed in a population selected according to these type I criteria, HNPCC mutation could be detected in 28% of cases.
  • In colorectal cancer surgery, the debate remains open on the place of coeliosurgery.
  • A US study has confirmed the prognostic value of the number of lymph nodes analyzed after resection of colorectal cancer.
  • In adjuvant treatment of stage II colon cancer, two contradictory publications have been reported in the Journal of Clinical Oncology.
  • However, the results of the Impact B2 Group are more consistent and support the fact that chemotherapy cannot be recommended as a standard treatment in state II colon cancer.
  • Concerning the chemotherapy of metastatic colorectal cancer, important results have been published in second line therapy showing the superiority of Campto compared to best supportive care or 5FU based chemotherapy both in term of overall survival and quality of life.
  • In first line chemotherapy, the superiority of bi-therapies (LV5FU2 and oxaliplatin or LV5FU2 and irinotecan) has been confirmed compared to LV5FU2 alone.
  • A recent publication showed that patients older than 70 years tolerate chemotherapy for colorectal cancer as well as younger patients with the same efficacy.
  • In esophagus carcinoma, the most important study didn't show any efficacy of neoadjuvant chemotherapy by 5FU-cisplatin in operable adenocarcinoma of squamous carcinoma of esophagus.
  • The final results of dutch's study in node dissection for gastric cancer do not find any benefit in overall survival comparing D2 versus D1 dissection with a substantial increase in morbidity and mortality in the D2 arm, specially when splenopancreatectomy was performed.
  • Finally, an important study has confirmed the value of per echoendoscopy biopsies for the diagnosis of positive lymph nodes and pancreatic tumors.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy, Needle / methods. Combined Modality Therapy. Genetic Testing. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Mass Screening / methods. Occult Blood

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10903787.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


15. Wang J, Jiang Y, Li J, Tian S, Ran W, Xiu D: Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res; 2009;28:88
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma.
  • BACKGROUND: To assess the feasibility and efficacy of using 125I seed implantation under intraoperative ultrasound guidance for unresectable pancreatic carcinoma.
  • METHODS: Fourteen patients with pancreatic carcinoma that underwent laparotomy and considered unresectable were included in this study.
  • Nine patients were pathologically diagnosed with Stage II disease, five patients with Stage III disease.
  • Fourteen patients were treated with 125I seed implantation guided by intraoperative ultrasound and received D90 of 125I seeds ranging from 60 to 140 Gy with a median of 120 Gy.
  • Five patients received an additional 35-50 Gy from external beam radiotherapy after seed implantation and six patients received 2-6 cycles of chemotherapy.
  • In this preliminary investigation, 125I seed implant provided excellent palliation of pain relief, local control and prolong the survival of patients with stage II and III disease to some extent.
  • [MeSH-major] Carcinoma / radiotherapy. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreas / pathology. Pancreas / radiography. Pancreas / ultrasonography. Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Dec 1;56(11):2563-8 [2864997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):759-63 [2984152.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Surg Gynecol Obstet. 1970 Jun;130(6):1049-53 [4192028.001]
  • [Cites] Cancer. 1983 Sep 1;52(5):808-13 [6191854.001]
  • [Cites] Ann Surg. 1984 Jan;199(1):1-5 [6419687.001]
  • [Cites] Pain Suppl. 1986;3:S1-226 [3461421.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):319-29 [3104244.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Ann Surg. 1988 Jun;207(6):648-54 [3389933.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2764-8 [7595736.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1357-62 [16029793.001]
  • [Cites] Radiother Oncol. 2005 Jul;76(1):48-53 [15990186.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):399-403 [16680642.001]
  • [Cites] Ann Surg. 1984 Sep;200(3):289-96 [6205632.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1705-10 [7284971.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):709-14 [6244074.001]
  • [Cites] Am J Surg. 1978 Feb;135(2):185-91 [626289.001]
  • (PMID = 19545454.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radioisotopes
  • [Other-IDs] NLM/ PMC2715376
  •  go-up   go-down


16. de Gramont A, Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology; 2005;69 Suppl 3:46-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
  • Bevacizumab (Avastin) has unprecedented survival benefit in patients with metastatic colorectal cancer.
  • Trials are already in progress to investigate the potential of bevacizumab in indications including metastatic renal cell cancer (RCC), non-small cell lung cancer (NSCLC), pancreatic cancer, breast and ovarian cancer.
  • Bevacizumab offers the potential to increase survival without substantially altering the toxicity profile in these tumor types.
  • In addition, combining bevacizumab with erlotinib (Tarceva) has shown a median time to progression of more than 11 months.
  • In NSCLC, a phase II trial revealed that adding bevacizumab to chemotherapy increased therapeutic benefit compared with chemotherapy alone.
  • Adverse events were mild and easily managed, but six patients receiving bevacizumab developed severe hemoptysis.
  • Adding bevacizumab (10 mg/kg) to the current standard of care, gemcitabine, in stage IV pancreatic cancer has also shown promising efficacy.
  • Several ongoing clinical trials are also studying bevacizumab with various chemotherapy and radiotherapy regimens.
  • Patients given chemotherapy (paclitaxel and carboplatin) plus bevacizumab had a higher response rate, longer PFS and an increase in survival compared with patients on chemotherapy alone.
  • Bevacizumab has also shown activity in patients with metastatic breast cancer.
  • Bevacizumab has the potential to provide significant efficacy benefits for patients with metastatic RCC, NSCLC, pancreatic cancer, and other tumor types when used first line in combination with standard therapy.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antibodies, Monoclonal / pharmacology. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Renal Cell / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy


17. Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella M: Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer; 2005 Sep 15;104(6):1237-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.
  • BACKGROUND: Gemcitabine infusion at the fixed dose rate of 10 mg/m(2) per minute (FDR-gemcitabine) has pharmacokinetic advantages and may result in improved therapeutic efficacy.
  • METHODS: Between April 2002 and September 2003, 40 patients with advanced-stage pancreatic adenocarcinoma (PDAC; n = 27) or biliary tree carcinoma (BTC; n = 13) were treated with weekly FDR-gemcitabine (1000 mg/m(2)).
  • The median time to treatment failure and the median PFS were 17 weeks (95% CI, 13-22 weeks) and 19 weeks (95% CI, 15-23 weeks), respectively.
  • Toxicity was mild with Grade 3-4 neutropenia (according to the National Cancer Institute-Common Toxicity Criteria [version 2.0]) in 18 of 427 treatment weeks (4.2%), and Grade 3 anemia and thrombocytopenia in 6 of 427 treatment weeks (1.4%) and 9 of 427 treatment weeks (2.1%), respectively, and asymptomatic Grade 3-4 transaminase elevation in 21 of 427 treatment weeks (4.9%).
  • CONCLUSIONS: FDR-gemcitabine at the weekly dose of 1000 mg/m(2) demonstrated promising activity, despite negligible toxicity, in patients with advanced-stage PDAC and BTC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16078261.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C: Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg; 2000 Apr;135(4):409-14; discussion 414-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of laparoscopic staging in the treatment of pancreatic cancer.
  • HYPOTHESIS: Staging laparoscopy in patients with pancreatic cancer identifies unsuspected metastases, allows treatment selection, and helps predict survival.
  • PATIENTS: A total of 125 consecutive patients with radiographic stage II to III pancreatic ductal adenocarcinoma who underwent staging laparoscopy with peritoneal cytologic examination between July 1994 and November 1998.
  • Seventy-eight proximal tumors and 47 distal tumors were localized.
  • INTERVENTIONS: Based on the findings of spiral computed tomography (CT) and laparoscopy, patients were stratified into 3 groups.
  • This group underwent external beam radiation with fluorouracil chemotherapy followed in selected cases by intraoperative radiation.
  • Patients in group 3 had no metastases or definitive vessel invasion and were resection candidates.
  • Fifty-five patients (44.0%) had localized but unresectable carcinoma (group 2), of whom 2 (3.6%) did not tolerate treatment, 20 (36.4%) developed metastatic disease during treatment, and 21 (38.2%) received intraoperative radiation.
  • CONCLUSIONS: Staging laparoscopy, combined with spiral CT, allowed stratification of patients into 3 treatment groups that correlated with treatment opportunity and subsequent survival.
  • Laparoscopic staging can help focus aggressive treatment on patients with pancreatic cancer who might benefit.
  • [MeSH-major] Carcinoma, Ductal, Breast / surgery. Laparoscopy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10768705.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Ishikawa T, Horimi T, Shima Y, Okabayashi T, Nishioka Y, Hamada M, Ichikawa J, Tsuji A, Takamatsu M, Morita S: Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder. J Hepatobiliary Pancreat Surg; 2003;10(3):233-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder.
  • BACKGROUND/PURPOSE: An aggressive approach is required to resect advanced carcinoma of the gallbladder.
  • Therefore, an extended surgical procedure often brings about a poor surgical outcome.
  • To test whether an aggressive surgical treatment can improve the survival rate for primary advanced carcinoma of the gallbladder, 59 patients with stage IV primary gallbladder carcinoma were studied.
  • METHODS: Patients were divided into three treatment groups for the survival analysis: group A (resectional surgery, n = 29), group B (low-dose cis-diamminedichloroplatinum-II and 5-fluorouracil therapy, n = 10), and group C (exploratory laparotomy, other treatment modalities, or no treatment, n = 20).
  • Also, there was no significant difference in the survival rate between the patients resected with distant metastasis (group A2) and chemotherapy cases (group B).
  • CONCLUSIONS: These results indicated that radical surgery should be performed for patients with no distant metastasis, and that chemotherapy might be a useful alternative treatment for patients with distant metastasis in advanced carcinoma of the gallbladder.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cholecystectomy / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy / methods. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14605981.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M: Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res; 2003 Sep 1;9(10 Pt 1):3679-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma.
  • PURPOSE: Retinoid analogues have been reported to inhibit the growth of hepatocellular carcinoma (HCC).
  • In this study, we investigated the expression of RAR mRNAs and proteins in resected HCC and nontumor liver tissue.
  • EXPERIMENTAL DESIGN: Reverse transcription-PCR and Western blot analysis were applied to investigate the expression of RAR mRNAs and proteins in 32 resected samples of HCC and 14 samples of nontumor liver tissue.
  • RESULTS: The intensities of mRNA and protein for RAR-alpha in HCC tissue were significantly higher than those in nontumor liver tissue (P = 0.002 and P = 0.002, respectively).
  • There was only one significant correlation between the higher intensity of RAR-beta protein and tumor stage (stage I/II versus stage III/IVA, P = 0.01) among clinicopathological variables in the HCC patients.
  • However, in vitro experiments showed that the growth of a RAR-alpha-elevated HCC cell line was potently inhibited by treatment with retinoids at concentrations that did not affect the growth of primary-cultured hepatocytes.
  • CONCLUSIONS: These results imply that RAR-alpha is the dominant receptor in HCC, which suggests that RAR-alpha-selective retinoid analogues may be useful for chemotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Receptors, Retinoic Acid / biosynthesis
  • [MeSH-minor] Blotting, Western. Cell Division. Cell Line, Tumor. Cell Nucleus / metabolism. Dose-Response Relationship, Drug. Humans. Liver / metabolism. Neoplasms / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506158.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 0 / retinoic acid receptor gamma
  •  go-up   go-down


21. Sunamura M, Kobari M, Shibuya K, Takeda K, Matsuno S: [The role of preoperative staging for pancreatic cancer]. Nihon Geka Gakkai Zasshi; 2000 Feb;101(2):212-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of preoperative staging for pancreatic cancer].
  • Despite the poor prognosis of pancreatic carcinoma patients, surgical resection remains the only potentially curative treatment.
  • According to the report of a national survey of pancreatic cancer in 1997, patients with S0 or S1, RP0 or RP1, and N0 or N1 disease have longer survival periods compared with patients with S2, RP2, and N2 disease.
  • Therefore patients classified as Stage I, Stage II, or Stage III are recognized as candidates for surgical resection.
  • Patients classified as Stage IVb because of positive P factor or positive H factor are selected for conservative treatment such as chemotherapy and irradiation.
  • It remains to be clarified whether patients classified as Stage IVa should undergo surgical resection or not.
  • Future prospective randomized studies of patients with Stage IVa disease will reveal whether surgical resection or chemoradiation is effective.
  • Helical CT is useful to evaluate S and RP factors for definitive preoperative staging.
  • [MeSH-major] Neoplasm Staging / methods. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10734639.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


22. Oettle H, Arnold D, Esser M, Huhn D, Riess H: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs; 2000 Sep;11(8):635-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.
  • Although the prognosis for patients with pancreatic adenocarcinoma is still poor, gemcitabine has shown significant impact upon survival and quality of life.
  • Our aim was to examine the potential effectiveness of a second- or third-line therapy with paclitaxel (Taxol) after confirmed progression with a gemcitabine-containing schedule for patients remaining in good clinical condition.
  • Eighteen patients with stage IVb disease participated in this study.
  • We observed 238 weekly treatments with a median number per patient of 12 treatments.
  • Hepatotoxicity with a temporary increase in aminotransferase of WHO grade II occurred in three patients.
  • At this time, the median survival time is 17.5 weeks (range 7-88 weeks) since the start of therapy.
  • At this time, he has survived for more than 56 weeks after confirmed progression under first-line therapy.
  • In conclusion, this schedule demonstrates that weekly therapy with paclitaxel after pretreatment can be effective with a low toxicity profile.
  • This opens up an additional therapeutic option for a selected patient group with a poor prognosis so far.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Paclitaxel / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prognosis. Quality of Life. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11081455.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM: A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol; 2007 Nov;14(11):3202-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
  • AIM: To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and capecitabine in patients with advanced biliary cancer.
  • All patients completed the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Pancreatic Cancer Module (EORTC QLQ-C30-PAN 26) questionnaire on day 1 of each cycle.
  • The two-stage design required 17 patients to evaluate the confirmed response at nine weeks.
  • Four out of seven patients with CBR had no decline in QOL with chemotherapy.
  • There were no treatment-related deaths.
  • CONCLUSIONS: Gemcitabine and capecitabine at this dose and schedule are well tolerated and effective and may offer clinical benefit and maintain QOL in patients with advanced biliary cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705089.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM: Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol; 2006 Jul;13(7):933-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma.
  • BACKGROUND: Long-term survival of surgically resectable pancreatic cancer patients is uncommon.
  • The epidermal growth factor receptor (EGFR) and the phosphoinositol-3-kinase pathways are often activated in pancreatic cancer, and an understanding of their role in resected cases may help refine adjuvant therapy.
  • Thirty-nine consecutive surgically resected pancreatic adenocarcinoma cases were included.
  • RESULTS: Patient characteristics were as follows: 17 men and 22 women; median age, 66 years; and American Joint Committee on Cancer stage I, 5 patients; stage II, 4 patients; stage III, 27 patients; and stage IV, 3 patients.
  • Adjuvant therapies were chemotherapy (n = 6), radiotherapy (n = 1), and chemoradiotherapy (n = 17).
  • CONCLUSIONS: p-Erk and p-Akt expression may have prognostic and therapeutic implications in pancreatic cancer.
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / surgery. Enzyme Activation. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation. Prognosis. Retrospective Studies. Survival Rate. Time Factors


25. Van Laethem JL, Demols A, Gay F, Closon MT, Collette M, Polus M, Houbiers G, Gastelblum P, Gelin M, Houtte PV, Closset J: Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys; 2003 Jul 15;56(4):974-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
  • PURPOSE: The addition of radiation to adjuvant 5-fluorouracil for the treatment of pancreatic cancer has not yet shown any definite benefit.
  • Gemcitabine (GEM) has potential activity in advanced pancreatic cancer and is a powerful radiosensitizer.
  • We evaluated the feasibility of postoperative administration of GEM alone, followed by concurrent GEM and irradiation (RT) after curative resection for pancreatic adenocarcinoma.
  • METHODS AND MATERIALS: GEM 1000 mg/m(2) on Days 1 and 8 every 21 days for three courses was given within 8 weeks after surgery and was followed by GEM 300 mg/m(2) weekly +40 Gy in a split course.
  • Twenty-two patients (median age 59 years, range 39-74, Performance Status 0-1) with Stage II and III curatively resected pancreatic head adenocarcinoma were included.
  • All patients, except two, completed full chemoradiation; one received only 20 Gy because of both World Health Organization Grade 4 vomiting and thrombopenia and the other stopped RT after 32 Gy because of early disease progression.
  • No late toxicity developed.
  • CONCLUSION: This adjuvant regimen was well tolerated and can be easily administered after curative surgery for pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Radiotherapy, Adjuvant / adverse effects

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12829132.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


26. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • RESULTS: Pain in the epigastrium and obstructive jaundice were observed in 70% and 74.2% of these 178 patients, both of which were of significance (P < 0.001) between stage I, II and stage III, IV disease.
  • Only 18% of patients had pain in the back, 81.3% of whom belonged to the stage IV category.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-major] Pain / etiology. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Caponigro F: Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs; 2002 Sep;13(8):891-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
  • The toxicity profile observed in all completed phase I/II trials has been fairly similar, since gastrointestinal tract toxicity (nausea, vomiting and diarrhea) and fatigue have generally qualified as dose-limiting toxicity (DLT).
  • One objective response in a patient with pretreated non-small cell lung cancer (NSCLC) was observed.
  • Nausea, vomiting, diarrhea and myelosuppression represented DLTs in these studies, in which an encouraging clinical activity was observed, in particular in pancreatic carcinoma (lonafarnib plus gemcitabine) and in NSCLC (lonafarnib plus paclitaxel).
  • Single-agent phase I/II studies have shown that myelotoxicity and neurotoxicity are DLTs, intermittent schedule is probably better tolerated and antitumor activity is observed particularly in breast cancer.
  • A number of combination studies with R115777 have been carried out; taken as a whole, they show that the drug can be easily combined with several anticancer agents and phase III trials exploring the potential benefit from incorporation of R115777 into active chemotherapy regimens are indicated.
  • Two other FTIs are in an earlier stage of clinical development.
  • [MeSH-major] Alkyl and Aryl Transferases / antagonists & inhibitors. Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Piperidines / therapeutic use. Pyridines / therapeutic use. Quinolones / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12394276.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Piperidines; 0 / Pyridines; 0 / Quinolones; 192185-72-1 / tipifarnib; 193275-84-2 / lonafarnib; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


28. Terenziani M, D'Angelo P, Bisogno G, Boldrini R, Cecchetto G, Collini P, Conte M, De Laurentis T, Ilari I, Indolfi P, Inserra A, Piva L, Siracusa F, Spreafico F, Tamaro P, Lo Curto M: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer; 2010 Apr;54(4):532-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC.
  • RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1).
  • Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1).
  • Three patients were in stage I, four in stage II, three in stage III, and four in stage IV.
  • All but one patient underwent surgery and only females showed carcinoma components.
  • Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive.
  • Malignant GCT warrants GCT-directed chemotherapy.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049928.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, Moore MJ: A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium. Invest New Drugs; 2007 Dec;25(6):553-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
  • Therefore, a phase II study of gemcitabine plus 3-AP in advanced pancreatic carcinoma was undertaken.
  • In this two-step phase II trial, patients with advanced pancreatic adenocarcinoma who had not received prior chemotherapy for advanced disease were treated with 3-AP 105 mg/m(2) given over 2 h.
  • Both drugs were given on days 1, 8 and 15 of a 28-day cycle.Twenty-six patients were enrolled to the study.
  • One patient withdrew consent prior to receiving any treatment and is excluded from all further analyses.
  • Four patients discontinued treatment due to adverse effects.
  • The median time to progression was 4.1 months and the 6 month progression-free survival rate was 29%.
  • The combination of 3-AP and gemcitabine is associated with moderate toxicity in patients with advanced pancreatic cancer.
  • This two-stage trial was stopped after stage I due to lack of antitumour activity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Pyridines / administration & dosage. Ribonucleotide Reductases / antagonists & inhibitors. Thiosemicarbazones / administration & dosage. Treatment Failure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2003 Dec;27(12 ):1077-83 [12921943.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6982-91 [16192585.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):676-85 [16847885.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1553-63 [15117978.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4092-100 [14519631.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1654-61 [16085692.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):331-42 [15148626.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):223-9 [12203104.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • (PMID = 17585372.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyridines; 0 / Thiosemicarbazones; 0W860991D6 / Deoxycytidine; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


30. Li Z, Sclabas GM, Peng B, Hess KR, Abbruzzese JL, Evans DB, Chiao PJ: Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer; 2004 Jul 1;101(1):58-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of synuclein-gamma in pancreatic adenocarcinoma.
  • BACKGROUND: Currently, pancreatic adenocarcinoma is the fourth leading cause of cancer-related death in the United States.
  • Despite the advances in pancreatic carcinoma research, patients with this devastating disease have a very poor prognosis.
  • To identify the gene expression profile of pancreatic carcinoma, an important step in the process of developing new diagnostic and therapeutic strategies, the authors investigated the alteration of gene expression in this disease.
  • METHODS: The authors analyzed a public serial analysis of gene expression (SAGE) database and examined in greater detail the expression of synuclein-gamma mRNA in several pancreatic carcinoma cell lines and tumor tissue samples by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis and Northern blot analysis.
  • The expression of synuclein-gamma protein was investigated further by immunohistochemical and Western blot analyses using tumor cell lines, tumor tissue, and serum samples.
  • RESULTS: Synuclein-gamma mRNA was overexpressed in 11 of 12 pancreatic carcinoma cell lines, including AsPc-1, MDAPanc28, Capan-1, Capan-2, PANC-1, HS766T, MDAPanc3, MDAPanc48, Colo357FG, MiaPaCa2, CFPac1, and BxPc3.
  • The expression of synuclein-gamma protein was detectable in 8 of 12 pancreatic carcinoma cell lines (67%) and in 22 of 32 pancreatic tumor tissue samples (69%) by Western blot analysis.
  • On immunohistochemical staining, synuclein-gamma protein was present in 61% of the tumor tissue samples examined from patients with Stage I and II pancreatic carcinoma.
  • Synuclein-gamma protein also was detectable by Western blot in serum samples from 21 of 56 patients (38%) with pancreatic carcinoma.
  • CONCLUSIONS: Synuclein-gamma, which initially was described as a breast carcinoma-specific gene involved in invasion, metastasis, and chemotherapy resistance, was frequently overexpressed in pancreatic carcinoma.
  • Overexpression of synuclein-gamma may play a role in pancreatic carcinoma invasion.
  • Further studies will be necessary to determine the role of synuclein-gamma in pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Nerve Tissue Proteins / biosynthesis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15221989.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 73675; United States / NCI NIH HHS / CA / CA 75517; United States / NCI NIH HHS / CA / CA 78778
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins; 0 / Synucleins
  •  go-up   go-down


31. Moutardier V, Turrini O, Huiart L, Viret F, Giovannini MH, Magnin V, Lelong B, Bories E, Guiramand J, Sannini A, Giovannini M, Houvenaeghel G, Blache JL, Moutardier JC, Delpero JR: A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg; 2004 May-Jun;8(4):502-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience.
  • Resection of localized pancreatic head ductal adenocarcinoma (LPHDA) has a limited impact on survival.
  • Mechanisms of improvement provided by preoperative chemoradiation therapy (CRT) remain under debate.
  • Thirty-nine with initially resectable cancers received CRT with 5-fluorouracil-based chemotherapy (group II).
  • Patients in groups II and III were restaged after completion of CRT.
  • Patients in groups I and II were statistically comparable in terms of age, sex, and pretherapeutic stage.
  • In group II, 23 patients (59%) had a pancreaticoduodenectomy (group IIa) and 16 patients (41%) did not have resection (group IIb).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / radiotherapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):264-9 [7754633.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1917-24 [11064348.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):758-65 [11776488.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] J Gastrointest Surg. 2001 Mar-Apr;5(2):121-30 [11331473.001]
  • [Cites] World J Surg. 1999 Sep;23(9):937-45 [10449824.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):860-7 [10673529.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):71-7; discussion 77-8 [7818001.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Int J Pancreatol. 1990 Aug-Nov;7(1-3):177-85 [2081923.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):747-8 [11776483.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Arch Surg. 1993 May;128(5):559-64 [8098206.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2920-7 [9256136.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Am J Clin Pathol. 1999 Nov;112(5):635-40 [10549250.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35 [11309645.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Arch Surg. 1991 Jul;126(7):885-9 [1854249.001]
  • [Cites] Arch Surg. 2000 Jan;135(1):81-7; discussion 88 [10636353.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2537-44 [12011133.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • (PMID = 15120377.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Fleming DR, Glisson SD, Bhupalam L, Michelson GD, Goldsmith GH, LaRocca RV: Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies. Am J Clin Oncol; 2000 Aug;23(4):349-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase I study was designed to evaluate the toxicity of escalating doses of gemcitabine along with fixed-dose paclitaxel in patients heavily pretreated with chemotherapy or radiotherapy.
  • All patients had no prior therapy with the study drugs and possessed both adequate performance and end organ function.
  • Characteristics included a median age of 66 years (range, 41 to 77) and stage IV disease in all patients; there were six patients with colon cancer, two with bladder cancer, three with non-small-cell lung cancer, two with esophageal cancer, three with pancreatic cancer, and two with cancer of unknown primary.
  • The treatment cycled every 21 days.
  • The combination of gemcitabine and paclitaxel seems to be well tolerated, and the recommended starting dose for a phase II study, in pretreated patients using a day 1/day 8 treatment schedule, should be 900 mg/m2 for gemcitabine (days 1 and 8) along with 150 mg/m2 for paclitaxel (day 1).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Colonic Neoplasms / drug therapy. Diarrhea / chemically induced. Esophageal Neoplasms / drug therapy. Exanthema / chemically induced. Female. Humans. Lung Neoplasms / drug therapy. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neoplasms, Unknown Primary / drug therapy. Neutropenia / chemically induced. Pancreatic Neoplasms / drug therapy. Paresthesia / chemically induced. Urinary Bladder Neoplasms / drug therapy. Vomiting / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955861.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


33. Fu P, Dowlati A, Schluchter M: Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival. J Clin Oncol; 2009 Sep 1;27(25):4135-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Enrichment based on molecular characteristics has emerged as an important inclusion criterion in phase II trials of targeted anticancer agents.
  • In this study, we evaluate a well-described method of population enrichment by tumor growth characteristics in the early development stage of targeted cytostatic agents.
  • METHODS: For some solid tumors, such as pancreatic carcinoma, using a time-to-event end point (eg, time to disease progression) to evaluate the efficacy of a cytostatic agent in a phase II trial is more relevant than clinical response by Response Evaluation Criteria in Solid Tumors.
  • In this setting, we compared the power of the randomized discontinuation and upfront randomization designs under two previously proposed tumor growth models for treatment effect when the end point is time-to-event.
  • RESULTS: By selecting patients with more homogeneous tumor growth characteristics, the randomized discontinuation design is more efficient than the upfront randomization design when treatment benefit is restricted to slow-growing tumors.
  • Under a model where only a subset of patients expressing the molecular target are sensitive to the agent, the randomized discontinuation design is more powerful than the upfront randomization design when the treatment effect is small; and vice versa when the treatment effect is moderate to large.
  • CONCLUSION: For selected targeted agents where a bioassay to select patients expressing the specific molecular target is not available, the randomized discontinuation design is a feasible alternative patient enrichment strategy in certain disease settings and provides a reasonable platform to evaluate drugs before phase III testing.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):785-91 [11157032.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1346-54 [18285606.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4478-84 [12431972.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2339-47 [12788999.001]
  • [Cites] Control Clin Trials. 2004 Apr;25(2):168-77 [15020035.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Epidemiol. 1993 Sep;46(9):959-71 [8263581.001]
  • [Cites] Control Clin Trials. 1998 Apr;19(2):178-87 [9551282.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5094-8 [15983399.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7199-206 [16192604.001]
  • [Cites] Biophys J. 2005 Dec;89(6):3884-94 [16199495.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):60-70 [16774933.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3370-9 [17545545.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61 [17895472.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):25-9 [17845846.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):8-11 [17981025.001]
  • [Cites] Oncologist. 2002;7(5):401-9 [12401902.001]
  • (PMID = 19636018.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062502; United States / NCI NIH HHS / CA / U01 CA62502
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2734425
  •  go-up   go-down


34. Javle M, Hsueh CT: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol; 2009 Feb 23;2:9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
  • The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment.
  • The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen.
  • Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment.
  • Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy.
  • Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit.
  • Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer.
  • The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy.
  • Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer.
  • Sorafenib is an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility in child's B cirrhosis remains to be proven.
  • Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease.
  • [MeSH-major] Carcinoma / therapy. Congresses as Topic. Gastrointestinal Neoplasms / therapy. Medical Oncology / trends
  • [MeSH-minor] Biliary Tract Neoplasms / therapy. Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / trends. Humans. Liver Neoplasms / therapy. Neoplasm Metastasis. Neoplasm Staging / methods. Pancreatic Neoplasms / therapy. Societies, Medical

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg Oncol. 2012 Jan;19(1):68-74 [21879261.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1210-4 [15277260.001]
  • [Cites] J Biol Chem. 1990 May 15;265(14):7709-12 [2186024.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):394-400 [16421419.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4914-21 [17050875.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):326-31 [17235048.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3205-9 [17664467.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4557-61 [17876013.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):734-8 [18272912.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3385-90 [19414665.001]
  • [Cites] J Nucl Med. 2009 Jul;50(7):1036-41 [19525451.001]
  • [Cites] J Clin Oncol. 2010 Jul 20;28(21):3491-7 [20530271.001]
  • [Cites] J Thorac Oncol. 2010 Sep;5(9):1472-6 [20631636.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • (PMID = 19236713.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2654905
  •  go-up   go-down


35. Boadas J, Balart J, Capellà G, Lluís F, Farré A: Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy. Rev Esp Enferm Dig; 2000 May;92(5):316-25
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy.
  • OBJECTIVE: The ominous prognosis of pancreatic carcinoma (PC) has led to a nihilistic attitude among physicians, and to the need to develop better tools for diagnosis, staging and treatment.
  • The aim of this study was to analyze a series of patients with PC in order to determine stage-related survival, and to try to improve diagnostic and therapeutic strategies.
  • TNM stage and survival were calculated.
  • We also analyzed age, sex, time elapsed until diagnosis, diagnostic tests, size and location, cytologic pathology confirmation, number of patients undergoing surgery, and procedures used.
  • Time elapsed until diagnosis: 3 +/- 15.7 months.
  • TNM staging: stage I 13%; stage II 25%; stage III 20%; stage IV 42%.
  • Stage-related survival: stage I 14 months; stage II 6 months; stage III 4 months; stage IV 1 month.
  • In 55% of the patients surgery revealed a higher stage of disease than had been diagnosed preoperatively.
  • CONCLUSIONS: Diagnosis was made at a late stage in many patients.
  • Early diagnosis, preoperative staging and postoperative management should be improved in these patients, and surgery should be associated with complementary chemotherapy and/or radiotherapy.
  • [MeSH-major] Pancreatic Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10927931.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


36. Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J: A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res; 2004 Sep 15;10(18 Pt 1):6086-93
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
  • Based on in vivo superadditive interaction between the protein kinase C-alpha antisense oligonucleotide LY900003 (Affinitak, ISIS 3521) and cisplatin, we designed this phase I/II trial of LY900003 with cisplatin/gemcitabine.
  • The phase II portion evaluated the antitumor activity of the combination in previously untreated patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
  • However, due to a relatively high frequency of thrombocytopenia, cisplatin 80 (mg/m2) and gemcitabine (1,000 mg/m2) were recommended for the phase II portion.
  • Antitumor activity was observed in two patients (one with NSCLC and one with pancreatic carcinoma), and prolonged stabilization was observed in two others.
  • In the phase II portion, 55 NSCLC patients received the combination at two gemcitabine doses [1,000 mg/m2, n=44 (original cohort); 1,250 mg/m2, n=11 (expanded cohort)].
  • Fourteen of 39 evaluable patients in the original cohort had a response rate (1 complete response and 13 partial responses; response, 36%), whereas 2 of 9 evaluable patients in the expanded cohort experienced partial response (combined response rate, 33%).
  • The median time to treatment failure was 3.9 months, whereas the median time response to progression for the 48 patients with evaluable response was 4.4 months (confidence interval, 3.5-5.5 months).
  • Intent to treat median survival time was 8.9 months.
  • Better characterization of subsets of patients most likely to benefit from this combination therapy is needed.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors / pharmacology. Lung Neoplasms / drug therapy. Oligodeoxyribonucleotides, Antisense / therapeutic use. Oligonucleotides, Antisense / pharmacology. Protein Kinase C / antagonists & inhibitors. Thionucleotides / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Oligonucleotides / chemistry. Protein Kinase C-alpha. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15447994.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Oligonucleotides; 0 / Oligonucleotides, Antisense; 0 / Thionucleotides; 0W860991D6 / Deoxycytidine; 151879-73-1 / ISIS 3521; B76N6SBZ8R / gemcitabine; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Kelly RJ, Rixe O: Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol; 2009 Dec;4(4):297-305
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas.
  • Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Drug Delivery Systems. Imidazoles / administration & dosage. Indazoles / administration & dosage. Lung Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / administration & dosage
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Mice. Mice, Nude. Neoplasm Transplantation. Signal Transduction. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 1999 Apr;161(1):41-9 [10194527.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23 (5):1028-43 [15534359.001]
  • [Cites] N Engl J Med. 1974 Jan 24;290(4):193-7 [4808917.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4708-13 [18541897.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Biol Chem. 2002 Oct;383(10):1573-9 [12452433.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Nat Med. 2006 Jul;12(7):793-800 [16799557.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Lancet Oncol. 2007 Nov;8(11):975-84 [17959415.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):127-32 [18183025.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):4047-8 [18711201.001]
  • [Cites] Cytogenet Cell Genet. 1995;70(1-2):145-6 [7736781.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):815-21 [17968174.001]
  • [Cites] Trends Biochem Sci. 2003 Sep;28(9):488-94 [13678960.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5474-83 [16027439.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1569-79 [7478581.001]
  • [Cites] J Thorac Oncol. 2006 Oct;1(8):768-70 [17409958.001]
  • [Cites] Mol Cancer. 2003 Jan 07;2:8 [12556241.001]
  • [Cites] Lancet. 2008 Jun 21;371(9630):2101-8 [18514303.001]
  • [Cites] Oncogene. 1997 May 1;14(17):2079-89 [9160888.001]
  • [Cites] APMIS. 2003 Mar;111(3):439-43 [12752224.001]
  • [Cites] Cell. 2008 Apr 18;133(2):223-34 [18423195.001]
  • [Cites] Magn Reson Imaging. 2007 Apr;25(3):319-27 [17371720.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7272-83 [19010843.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1677-83 [1656371.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2155-60 [3902203.001]
  • (PMID = 19876699.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Indazoles; 0 / Vascular Endothelial Growth Factor A; C9LVQ0YUXG / axitinib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


38. Moore AS, Nelson RW, Henry CJ, Rassnick KM, Kristal O, Ogilvie GK, Kintzer P: Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999). J Am Vet Med Assoc; 2002 Sep 15;221(6):811-8
Hazardous Substances Data Bank. STREPTOZOTOCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999).
  • OBJECTIVE: To determine toxic effects of streptozocin given in combination with a diuresis protocol in dogs and establish whether streptozocin is efficacious in treatment of pancreatic islet cell tumors in dogs.
  • PROCEDURE: Medical records were reviewed to obtain information regarding signalment, tumor stage and staging tests performed, number of streptozocin treatments, adverse effects, results of biochemical and hematologic monitoring during streptozocin treatment, tumor dimensions, duration of normoglycemia, and date of death, when applicable.
  • RESULTS: 58 treatments were administered to the 17 dogs.
  • Only 1 dog developed azotemia.
  • Serum alanine aminotransferase activity increased in some dogs but decreased when treatment was discontinued.
  • Two dogs developed diabetes mellitus after receiving 5 doses.
  • Median duration of normoglycemia for 14 dogs with stage-II or -III insulinoma treated with streptozocin was 163 days (95% confidence interval, 16 to 309 days), which was not significantly different from that for the control dogs (90 days; 95% confidence interval, 0 to 426 days).
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Islet Cell / veterinary. Dog Diseases / drug therapy. Pancreatic Neoplasms / veterinary. Streptozocin / therapeutic use
  • [MeSH-minor] Animals. Dogs. Female. Male. Neoplasm Staging / veterinary. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12322919.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5W494URQ81 / Streptozocin
  •  go-up   go-down


39. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem; 2009;44(1):29-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of metallothionein in oncogenesis and cancer prognosis.
  • The antiapoptotic, antioxidant, proliferative, and angiogenic effects of metallothionein (MT)-I+II has resulted in increased focus on their role in oncogenesis, tumor progression, therapy response, and patient prognosis.
  • Studies have reported increased expression of MT-I+II mRNA and protein in various human cancers; such as breast, kidney, lung, nasopharynx, ovary, prostate, salivary gland, testes, urinary bladder, cervical, endometrial, skin carcinoma, melanoma, acute lymphoblastic leukemia (ALL), and pancreatic cancers, where MT-I+II expression is sometimes correlated to higher tumor grade/stage, chemotherapy/radiation resistance, and poor prognosis.
  • However, MT-I+II are downregulated in other types of tumors (e.g. hepatocellular, gastric, colorectal, central nervous system (CNS), and thyroid cancers) where MT-I+II is either inversely correlated or unrelated to mortality.
  • Large discrepancies exist between different tumor types, and no distinct and reliable association exists between MT-I+II expression in tumor tissues and prognosis and therapy resistance.
  • Furthermore, a parallel has been drawn between MT-I+II expression as a potential marker for prognosis, and MT-I+II's role as oncogenic factors, without any direct evidence supporting such a parallel.
  • This review aims at discussing the role of MT-I+II both as a prognostic marker for survival and therapy response, as well as for the hypothesized role of MT-I+II as causal oncogenes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348910.001).
  • [ISSN] 0079-6336
  • [Journal-full-title] Progress in histochemistry and cytochemistry
  • [ISO-abbreviation] Prog Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9038-94-2 / Metallothionein
  • [Number-of-references] 203
  •  go-up   go-down


40. Jakobisiak M, Golab J: Potential antitumor effects of statins (Review). Int J Oncol; 2003 Oct;23(4):1055-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statins, which have been introduced to the clinic for the treatment of hypercholesterolemia, are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the major rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid (MA).
  • They have also been found to display antitumor effects against melanoma, mammary carcinoma, pancreatic adenocarcinoma, fibrosarcoma, glioma, neuroblastoma, and lymphoma in animal tumor models resulting in retardation of tumor growth, and/or inhibition of the metastatic process.
  • The results of several clinical studies of statins in cancer patients including phase I, phase I/II, and phase II trials have been published.
  • Although evaluation of the therapeutic efficacy is not the purpose of early clinical trials and all conclusions might be premature at this stage, some preliminary conclusions have already been drawn.
  • The results of these studies do not show any significant therapeutic effects of statins in cancer patients.
  • However, the results of one of these studies suggest that statins could effectively strengthen the therapeutic activity of some chemotherapeutics.
  • However, as toxic side effects of statins have been particularly evident in their combination with some other drugs great caution should be advised while planning clinical trials based on combination therapy including statins in cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12963986.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Number-of-references] 230
  •  go-up   go-down






Advertisement